ByTrending Posts
Will GE HealthCare’s Acquisition of icometrix Redefine AI-Powered…
Chicago – GE HealthCare (Nasdaq: GEHC) announced it has entered into a definitive agreement to acquire icometrix, a…
Can BD’s Expanded Recall of Alaris™ Pump Infusion…
Key Insights BD’s updated recall follows internal testing that revealed infusion performance deviations, including flow rate accuracy issues,…
Can Johnson & Johnson’s Pact with Pacira BioSciences…
Key Insights Expanding Non-Surgical Pathways Through this agreement, Johnson & Johnson MedTech integrates ZILRETTA® into its Early Intervention…
Will BioNTech and Pfizer’s Counterstrike Against GSK Reshape…
Key Insights GSK’s Offensive Meets Resistance GSK launched a sweeping litigation campaign in 2024, targeting BioNTech and Pfizer…
Can LB Pharmaceuticals’ $285M IPO Reignite Investor Confidence…
Key Insights IPO Breaks Market Drought LB Pharmaceuticals, a CNS-focused biotech, has defied a months-long IPO drought by…
Is Merck’s £1B Exit Forcing AstraZeneca, Lilly, and…
Key Insights Merck Triggers Domino Effect with £1B Withdrawal Merck’s decision to abandon its £1-billion London R&D facility…
Can DeepMind’s Demis Hassabis Slash Drug Discovery Timelines…
Key Highlights: What Hassabis Says: A Turning Point for Drug DiscoveryDemis Hassabis, CEO of DeepMind, recently told Bloomberg…
Will AbbVie’s Rinvoq Patent Deal Lock Out Generics…
Key Highlights: Patent Shield Extended Through SettlementsAbbVie has successfully resolved litigation with multiple generic challengers—including Sandoz, Aurobindo, Intas,…
Will Johnson & Johnson’s FDA Approval of INLEXZO™…
Key Highlights: A Breakthrough in Bladder Cancer TreatmentThe U.S. FDA has approved INLEXZO™ (gemcitabine intravesical system), marking the…
Trending Posts
Latest Stories
Is Novartis Bolstering Its Radioligand Oncology Pipeline at JPM 2026 with a Radioligand Peptide Program Acquisition?
Basel / San Francisco | January 2026 Novartis has expanded its precision oncology strategy with a…
Is Pfizer’s $10 Billion Metsera Acquisition at JPM2026 a Defining Move in the Obesity and Cardiometabolic Race?
San Francisco / New York | January 2026 Pfizer has made a decisive strategic move…
Is Amgen Bolstering Its Oncology Pipeline at JPM 2026 with an $840 Million Dark Blue Therapeutics Acquisition?
Thousand Oaks, U.S. | January 2026 Amgen has expanded its oncology growth strategy with the…
Is AstraZeneca’s Acquisition of Modella AI at JPM 2026 a Signal That Pharma Is Internalizing AI for R&D?
Cambridge, U.K. | January 2026 AstraZeneca has taken a decisive step to deepen its artificial…
Gallery
